Neovacs sets up JV with Stellar Biotechnologies

21 January 2016

French biotech firm Neovacs (Alternext Paris: ALNEV) said today it has signed a partnering agreement with the American company Stellar Biotechnologies (Nasdaq: SBOT) to establish a joint venture, which will operate under the name of Neostell SAS, and it will be owned 30% by Stellar and 70% by Neovacs.

Stellar Biotechnologies is a leading manufacturer of Keyhole Limpet Hemocyanin (KLH), a carrier protein largely utilized in the production of on conjugated vaccines for its immune stimulating properties. Stellar has been the supplier of KLH to Neovacs for many years. This carrier protein is a strategic component in the production of IFNα-Kinoid. Neovacs' and Stellar's current collaboration will be strengthened through this project, which is strategic for both partners.

The objective of the newly-formed Neostell SAS is to produce:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK